Related references
Note: Only part of the references are listed.Coiled-Coil Domain-Containing 68 Downregulation Promotes Colorectal Cancer Cell Growth by Inhibiting ITCH-Mediated CDK4 Degradation
Cong Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Regulatory Mechanism of MicroRNA Expression in Cancer
Zainab Ali Syeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST
Xiao Yang et al.
MOLECULAR CANCER (2020)
Molecular Mechanisms Driving mRNA Degradation by m(6)A Modification
Yujin Lee et al.
TRENDS IN GENETICS (2020)
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation
Chuanzhao Zhang et al.
ONCOGENE (2020)
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer
Xiaoxiang Chen et al.
MOLECULAR CANCER (2020)
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
Jiangfeng Li et al.
MOLECULAR CANCER (2020)
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer
Xiaofei Cheng et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma
Li Zhong et al.
CANCER LETTERS (2019)
The Critical Role of RNA m6A Methylation in Cancer
Qing Lan et al.
CANCER RESEARCH (2019)
The role of m6A RNA methylation in human cancer
Xiao-Yu Chen et al.
MOLECULAR CANCER (2019)
ZFP217 regulates adipogenesis by controlling mitotic clonal expansion in a METTL3-m6A dependent manner
Qing Liu et al.
RNA BIOLOGY (2019)
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Nithya Krishnamurthy et al.
CANCER TREATMENT REVIEWS (2018)
Targeted therapy for metastatic colorectal cancer
Timothy J. Price et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment
Jonathan Pearson-Stuttard et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Effect of exosomal miRNA on cancer biology and clinical applications
Zhenqiang Sun et al.
MOLECULAR CANCER (2018)
XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell
Chao Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
m6A in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression
Jean-Yves Roignant et al.
TRENDS IN GENETICS (2017)
YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells
Jixiang Chen et al.
CELL CYCLE (2017)
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Fang Geng et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
m6A-LAIC-seq reveals the census and complexity of the m6A epitranscriptome
Benoit Molinie et al.
NATURE METHODS (2016)
Cell Cycle Control: A System of Interlinking Oscillators
Randy Y. C. Poon
CELL CYCLE OSCILLATORS: METHODS AND PROTOCOLS (2016)
5′ UTR m6A Promotes Cap-Independent Translation
Kate D. Meyer et al.
CELL (2015)
N6-methyladenosine-dependent regulation of messenger RNA stability
Xiao Wang et al.
NATURE (2014)
Therapeutic targeting of microRNAs: current status and future challenges
Zhonghan Li et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
RNA-Methylation-Dependent RNA Processing Controls the Speed of the Circadian Clock
Jean-Michel Fustin et al.
CELL (2013)
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Hui Ling et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Ibuprofen Inhibits Activation of Nuclear beta-Catenin in Human Colon Adenomas and Induces the Phosphorylation of GSK-3 beta
Emily J. Greenspan et al.
CANCER PREVENTION RESEARCH (2011)
Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in ApcMin/+ mice
Kristoffer W. Brudvik et al.
MOLECULAR CANCER (2011)
miRBase: integrating microRNA annotation and deep-sequencing data
Ana Kozomara et al.
NUCLEIC ACIDS RESEARCH (2011)
Targeting microRNAs in cancer: rationale, strategies and challenges
Ramiro Garzon et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Increased Expression of β-Catenin, Phosphorylated Glycogen Synthase Kinase 3β, Cyclin D1, and c-myc in Laterally Spreading Colorectal Tumors
Jing Wang et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2009)
Knockin of mutant PIK3CA activates multiple oncogenic pathways
John P. Gustin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner
M. Caspi et al.
ONCOGENE (2008)
Detection of active fraction of glycogen synthase kinase 3 beta in cancer cells by nonradioisotopic in vitro kinase assay
Wei Mai et al.
ONCOLOGY (2006)
β-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: Relationships with carcinogenesis and metastasis
Yu-Jun Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Share Paper
